FDA is amending its regulations
governing the content and format of labeling for human prescription
drug products, including biological products, to include
information pertinent to the appropriate use of drugs in the
elderly (persons aged 65 and over) and to facilitate access to this
information by establishing a geriatric subsection in the labeling
as provided in #201.57(f)(10). FDA believes that improving access
to informaton that is important to the elderly will facilitate the
safe and effective use of prescription drugs in older
populations.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.